Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Hypothermic Kidney Machine Perfusion With Omnisol (OMNIPUMP)

30. oktober 2026 oppdatert av: Vivalyx GmbH

A Single-Center, Non-Randomized Safety Study on Hypothermic Machine Perfusion With Omnisol Preservation Solution of Deceased Donor Kidneys Prior to Transplantation

Insufficient availability of organs from brain dead (DBD) and living donors has necessitated increased use of less than optimal organs from donation after cardiac death (DCD) or from extended criteria donors. Preservation of DCD organs using the current clinically applied preservation solutions is associated with up to 73% incidence of delayed graft function, highlighting the need for new preservation solutions designed to improve early graft function.

Omnisol is expected to result in equivalent or improved kidney preservation as compared to currently marketed organ preservation solutions used for HMP.

Studieoversikt

Status

Har ikke rekruttert ennå

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

Hypothermic machine perfusion (HMP) is increasingly used for the preservation of deceased donor kidneys before transplantation. Omnisol was developed as an extracellular-type organ preservation solution for the flushing and HMP of donor kidneys.

Omnisol organ preservation solution was developed to improve kidney transplant outcomes. It is an extracellular-type solution containing the synthetic colloid polyethylene glycol (PEG) and several impermeants for optimal osmotic pressure. It further contains multiple buffering agents for the prevention of intracellular acidosis, antioxidants for the minimization of ROS-induced injury and amino acids and other substrates for supporting the cell metabolism during hypothermic machine perfusion (HMP) as well as the provision of substrates for regeneration of high-energy phosphate compounds during graft reperfusion.

This prospective, single-center, non-randomized clinical investigation is designed primarily to evaluate the safety of Omnisol when used for the wash-out and HMP of kidneys from deceased donors before transplantation. The investigation incorporates a retrospective matched-control design, where each recipient of a kidney preserved with Omnisol will be matched with two recipients previously transplanted at the same center with kidneys preserved by HMP using UW-MPS.

This study employs a back-to-base design, meaning that after arrival at the transplant center according to standard of care, the kidney is flushed with Omnisol and transferred to HMP using Omnisol in the standard of care perfusion machine until implantation.

Studietype

Intervensjonell

Registrering (Antatt)

16

Fase

  • Ikke aktuelt

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

Inclusion for donor:

  • Donor age > 18 years
  • Brain Death (DBD) or Circulatory Death (DCD)
  • Accepted for transplantation according to local criteria
  • For DCD donors: functional warm ischemia time (WIT) ≤ 30 minutes and total WIT ≤ 60 minutes
  • Cold ischemia time (CIT) prior to HMP with Omnisol no greater than 14 hours

Inclusion for recipient:

  • Male or female, age > 18 years
  • Able and willing to provide informed consent and comply with all study requirements (in opinion of investigator or deputy)
  • General inclusion criteria applicable to kidney transplantation:
  • Listed for renal transplantation due to end stage renal disease on OPO list
  • Able and willing to comply with all study requirements (in opinion of investigator or deputy)
  • Fit to proceed with kidney

Exclusion Criteria:

Exclusion for donor:

• Donor kidneys accepted as a pair for dual transplant

Exclusion for recipient:

  • General exclusion criteria applicable to kidney transplantation
  • Breast-feeding or pregnant, as confirmed by pregnancy test or blood test, or plans to become pregnant over the study period
  • Participation in an investigational study likely to affect interpretation of the trial data
  • Mental disabilities that may affect the understanding of the study requirements including the ability to adhere to medication regime (in opinion of investigator or deputy)
  • Undergoing living donor kidney transplantation
  • Undergoing dual kidney transplantation
  • Undergoing transplantation of other organ(s) in addition to the kidney
  • Highly sensitized patients with cPRA > 80% (based on routine HLA antibody assessment)
  • Positive donor-specific crossmatch, if performed per institutional standard practice
  • Other substantial risk of transplant not proceeding (in opinion of investigator or deputy)
  • Other significant disease or disorder which, in the opinion of the Investigator, may: (i) put the participant at risk by participating in the study; (ii) influence the result of the study; (iii) affect the participant's ability to participate in the study

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Donation after brain death (DBD)

Recipients of a kidney from a donor after brain death (DBD). After arrival at the transplant center according to standard of care, kidneys will be flushed with Omnisol and placed on the standard of care HMP machine for perfusion with Omnisol until transplantation.
Enhet: Omnisol organ preservation solution

Omnisol for HMP of DBD or DCD donors.
Eksperimentell: Donation after circulatory death (DCD)

Recipients of a kidney from a donor after circulatory death (DCD). After arrival at the transplant center according to standard of care, kidneys will be flushed with Omnisol and placed on the standard of care HMP machine for perfusion with Omnisol until transplantation.
Enhet: Omnisol organ preservation solution

Omnisol for HMP of DBD or DCD donors.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Incidence of Delayed Graft Function
Tidsramme: 7 days post-transplantation.

Incidence of delayed graft function, defined as the requirement for at least one dialysis session within the first 7 days after transplantation, excluding a single dialysis session performed solely for hyperkalemia or volume overload.
7 days post-transplantation.
Graft Survival
Tidsramme: 30 days post-transplantation.

30-day graft survival, censored and uncensored for recipient death.
30 days post-transplantation.

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Graft Survival
Tidsramme: 3, 6 and 12 months post-transplantation.

Graft survival, censored and uncensored for recipient death.
3, 6 and 12 months post-transplantation.
Recipient Survival
Tidsramme: 30 days, 3, 6 and 12 months post-transplantation.

Rate of recipient survival.
30 days, 3, 6 and 12 months post-transplantation.
Kidney Graft Function
Tidsramme: 30 days, 3, 6 and 12 months post-transplantation.

Estimated glomerular filtration rate (eGFR) calculated using the CKD-EPI creatinine equation.
30 days, 3, 6 and 12 months post-transplantation.
Primary Non-Function
Tidsramme: 30 days, 3, 6 and 12 months post-transplantation.

Incidence of irreversible graft failure with no initial evidence of graft function following transplantation.
30 days, 3, 6 and 12 months post-transplantation.
Duration of Delayed Graft Function
Tidsramme: 30 days post-transplantation.

Duration of delayed graft function in participants who require renal replacement therapy after kidney transplantation.
30 days post-transplantation.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Vivalyx GmbH

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. januar 2027

Primær fullføring (Antatt)

1. mai 2027

Studiet fullført (Antatt)

1. mai 2028

Datoer for studieregistrering

Først innsendt

30. oktober 2026

Først innsendt som oppfylte QC-kriteriene

30. oktober 2026

Først lagt ut (Faktiske)

6. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

6. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

30. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • OMNISOL_HMP_US

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Ja

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere